Personalized IRAK4 Degrader Therapies for MYD88-Mutant B-Cell Lymphomas
Legal Citation
Summary of the Inventive Concept
A next-generation approach to treating MYD88-mutant B-cell lymphomas, leveraging machine learning, artificial intelligence, and advanced biomarker analysis to develop personalized IRAK4 degrader therapies with enhanced efficacy and selectivity.
Background and Problem Solved
The original patent disclosed methods for treating MYD88-mutant B-cell lymphomas using IRAK4 degraders. However, these approaches have limitations, including variable patient responses and potential toxicities. The new inventive concept addresses these limitations by integrating cutting-edge technologies to create personalized treatment strategies that optimize patient outcomes.
Detailed Description of the Inventive Concept
The inventive concept comprises four key components: 1) novel IRAK4 degrader molecules with enhanced potency and selectivity, 2) machine learning-based predictive models for identifying patients most likely to respond to treatment, 3) customized combinations of IRAK4 degraders and immunomodulatory agents based on patient-specific genetic profiles and tumor characteristics, and 4) nanoparticle formulations for targeted delivery of IRAK4 degraders and immune checkpoint inhibitors to tumor cells. Additionally, the concept includes a wearable device for tracking biomarkers and a cloud-based analytics platform for identifying early signs of treatment resistance.
Novelty and Inventive Step
The new claims introduce a paradigm shift in the treatment of MYD88-mutant B-cell lymphomas by integrating machine learning, artificial intelligence, and advanced biomarker analysis to develop personalized therapies. This approach is novel and non-obvious compared to the original patent, which focused solely on the use of IRAK4 degraders.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include the use of different machine learning algorithms, varying nanoparticle formulations, or incorporating additional biomarkers for personalized treatment. Variations may also involve adapting the concept for treating other types of cancers or diseases.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the oncology market, with potential applications in personalized medicine, precision oncology, and immuno-oncology. The market for IRAK4 degraders and immunomodulatory agents is expected to grow significantly in the coming years, driven by increasing demand for targeted and effective cancer treatments.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Oncology, pharmaceutical biotechnology, with specific expertise in targeted molecular therapies for B-cell lymphomas, machine learning applications in precision medicine, and drug delivery systems
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in molecular biology or pharmaceutical sciences, understanding of cancer genetics, experience with targeted therapeutic development, and familiarity with computational biology techniques
Obviousness Rationale
A PHOSITA would recognize that the personalized approach to IRAK4 degrader therapy represents a natural progression of precision medicine principles already emerging in oncological treatment strategies. The integration of machine learning, biomarker analysis, and targeted delivery methods are logical extensions of existing therapeutic paradigms for MYD88-mutant lymphomas. The technical variations demonstrate incremental improvements that would be predictable to a skilled researcher working in targeted cancer therapeutics.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,535 |
|---|---|
| Title | Methods of treating mutant lymphomas |
| Assignee(s) | Kymera Therapeutics, Inc. |